S&P 500 Healthcare Sector SPDR (XLV)

Despite Agilent Technologies’ underperformance relative to its industry peers, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Although IDEXX Laboratories has outperformed the healthcare sector over the past year, analysts remain cautiously optimistic about the stock’s prospects.

While Cencora’s recent performance has lagged behind other healthcare stocks, analysts express strong confidence in its long-term growth potential.

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

Over the past year, CVS stock has outpaced the healthcare sector, garnering positive analyst sentiment and demonstrating sustained momentum.

HCA Healthcare has significantly outperformed the broader market over the past year, and analysts remain optimistic about the stock’s prospects.

Healthcare giant Stryker has notably underperformed the broader market over the past year, yet analysts remain optimistic about the stock’s prospects.

Merck has outperformed the healthcare sector over the past three months. Moreover, Wall Street analysts are moderately optimistic about its prospects.

Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Thermo Fisher Scientific has outperformed the broader healthcare sector over the past year, and analysts continue to hold a strongly bullish view on its growth prospects.